Liraglutide cost-effective vs other GLP-1 receptor agonists
Liraglutide 1.2 mg has proved cost-effective when compared to alternative daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK. The GLP-1 receptor agonist class has grown in the last decade in the UK, but there has been a lack of evidence about their relative cost-effectiveness due to a lack of head-to-head trial data.
This study used results from a network meta-analysis (NMA) to compare the cost-effectiveness of three daily administered GLP-1 receptor agonists in the UK. A validated diabetes model was used to make long-term projections of clinical outcomes and direct costs for people receiving liraglutide 1.2 mg once-daily, exenatide 10 μg twice daily and lixisenatide 20 μg once-daily.
The study showed that liraglutide 1.2 mg was associated with improved quality-adjusted life expectancy versus exenatide (9.19 vs 9.17 quality-adjusted life years (QALYs)) and lixisenatide (9.19 vs 9.12 QALYs). Improvements were driven by benefits in glycaemic control, leading to a reduced incidence of diabetes-related complications.
In addition, liraglutide was associated with reduced costs vs exenatide (£36,394 vs £36,547) and lixisenatide (£36,394 versus £36,496), with cost savings as a result of complications avoided entirely offsetting increased acquisition costs.
The researchers concluded that, “Liraglutide 1.2 mg is likely to be considered cost-effective versus alternative daily administered GLP-1 receptor agonists for treatment of type 2 diabetes in the UK.”
This study provides useful data on the comparative cost-effectiveness of liraglutide vs other GLP-1 receptor agonists. Further studies should be evaluated in order to make appropriate formulary/prescribing decisions.
Hunt B, et al. Evaluating the long-term cost-effectiveness of daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the United Kingdom. Diabetes Ther 2017, published online 5 Jan www.ncbi.nlm.nih.gov/pubmed/28058656
- NICE recommends three SGLT-2 inhibitors for type 2 diabetes
- GLP-1 mimetics in diabetes: what have we learned?